Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 53 min ago
Peer-reviewedCC BYFrontiers in aging neuroscience

Association of statin use with reduced risk of Alzheimer's disease: findings in UK Biobank.

  • Hui Yang1,2
  • Can Zhu1,2
  • Jialu He3
  • Yan Wei1,2
  • Dongmei Li2
  • Xuan Luo2
  • Ying Wang1,4,5
5 affiliations
  1. 1Department of Clinical Research Center, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, Zhejiang, China.
  2. 2School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  3. 3School of Public Health Management, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  4. 4Laboratory of Medicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, Zhejiang, China.
  5. 5Zhejiang Key Laboratory of Zero Magnetic Medicine, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Read full textPDFDOICite

Abstract

Background

Previous studies on the association between statin use and the risk of Alzheimer's disease (AD) have yielded inconsistent results. This study, based on the large-scale UK Biobank cohort, evaluates the relationship between statin use and the risk of new-onset AD, survival in patients with AD, and cognitive function.Methods

This study included 502,401 participants with a median follow-up of 9.24 years. The association between statin use and the risk of AD was analyzed using Cox proportional hazards models, logistic regression, and propensity score matching. The robustness of the results was assessed through internal validation using training and validation groups, as well as subgroup analyses.Results

A total of 975 new cases of AD were recorded. Multivariate Cox regression analysis showed that statin use was associated with a reduced risk of AD (HR = 0.72, 95% CI: 0.52-0.98; p < 0.05), and the results remained consistent after propensity score matching (p < 0.05). Among individuals aged ≥65 years, statin users demonstrated better cognitive performance than non-users. Concomitant use of antihypertensive or antidiabetic medications did not significantly alter the protective effect of statins.Conclusion

Statin use was associated with a modestly lower risk of AD and slower cognitive decline. These findings highlight the importance of enhanced clinical awareness in identifying AD patients and those at risk of adverse outcomes.

Related

  1. Contrastive learning and advanced bundle metrics outperform fractional anisotropy for Alzheimer’s disease diffusion MRI prediction: findings from the Beyond FA challenge
    Elyssa McMaster, Nancy Newlin, Trent Schwartz +31
    Journal of medical imaging (Bellingham, Wash.)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Healthy sleep pattern is associated with reduced risk of incident thyroid disease: a prospective cohort study from the UK Biobank
    Jingxue Sun, Yanmeizhi Wu, Xiaoyu Zhao +5
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEndocrinology & metabolismEurope PMCCrossref
  3. Reduced serum LEFTY2 and disease-dependent biomarker associations in Alzheimer's disease: an exploratory study.
    Wei Wuli, Raymond Y Lo, Horng-Jyh Harn +5
    Frontiers in aging neurosciencePeer-reviewedCC BYFull textPhysiologyEurope PMC
  4. Association of Nut Consumption with Dementia and Alzheimer’s Disease
    NutrientsPeer-reviewedCC BYFull textNutritionEurope PMC
  5. Acupuncture-related brain network findings across clinical stages of the Alzheimer’s disease continuum: a critical review of functional MRI evidence
    Xue Bai, Yahong Ji, Hengyu Ruan +5
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textNeurologyCrossrefDOAJ

Cite

BibTeXRIS
BibTeX
@article{yang2026association,
  title = {{Association of statin use with reduced risk of Alzheimer's disease: findings in UK Biobank.}},
  author = {Hui Yang and Can Zhu and Jialu He and Yan Wei and Dongmei Li and Xuan Luo and Ying Wang},
  journal = {Frontiers in aging neuroscience},
  year = {2026},
  month = oct,
  doi = {10.3389/fnagi.2026.1961033},
  url = {https://europepmc.org/article/MED/42903333},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Association of statin use with reduced risk of Alzheimer's disease: findings in UK Biobank.
AU  - Hui Yang
AU  - Can Zhu
AU  - Jialu He
AU  - Yan Wei
AU  - Dongmei Li
AU  - Xuan Luo
AU  - Ying Wang
PY  - 2026
DA  - 2026/10/06
JO  - Frontiers in aging neuroscience
DO  - 10.3389/fnagi.2026.1961033
UR  - https://europepmc.org/article/MED/42903333
AB  - Background  Previous studies on the association between statin use and the risk of Alzheimer's disease (AD) have yielded inconsistent results. This study, based on the large-scale UK Biobank cohort, evaluates the relationship between statin use and the risk of new-onset AD, survival in patients with AD, and cognitive function.Methods  This study included 502,401 participants with a median follow-up of 9.24 years. The association between statin use and the risk of AD was analyzed using Cox proportional hazards models, logistic regression, and propensity score matching. The robustness of the results was assessed through internal validation using training and validation groups, as well as subgroup analyses.Results  A total of 975 new cases of AD were recorded. Multivariate Cox regression analysis showed that statin use was associated with a reduced risk of AD (HR = 0.72, 95% CI: 0.52-0.98; p < 0.05), and the results remained consistent after propensity score matching (p < 0.05). Among individuals aged ≥65 years, statin users demonstrated better cognitive performance than non-users. Concomitant use of antihypertensive or antidiabetic medications did not significantly alter the protective effect of statins.Conclusion  Statin use was associated with a modestly lower risk of AD and slower cognitive decline. These findings highlight the importance of enhanced clinical awareness in identifying AD patients and those at risk of adverse outcomes.
SN  - 1663-4365
ER  -